Friday, July 17, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 20, 2026
Understanding Agentic AI in Clinical Development
background ▾
- •Agentic AI represents a shift from reactive task completion to autonomous, multi-step objective pursuit—a distinction with implications for how pharma organizations structure clinical workflows and cross-functional coordination
Syneos Health
→ Read original articlePolicy•STAT News•Jul 17, 2026
Why affirming trans identities can be critical for suicide prevention counseling
background ▾
- •Restored 988 LGBTQ+ services must comply with an executive order that denies transgender/nonbinary identity recognition, potentially forcing counselors to withhold affirming responses known to reduce suicide risk in this population.
- •The Trevor Project's continued role in the restored 988 line is uncertain due to application technicalities, despite having operated youth crisis services since 1998 and handling ~50% of specialized calls since 2022's launch.
- •Mental health advocates warn that restricting identity affirmation during crisis calls could increase harm; watch for details on counselor training guidelines and whether the administration enforces compliance mechanisms that conflict with clinical best practices.
The Trevor ProjectLGBT National Help Center
→ Read original articlePolicy•STAT News•Jul 17, 2026
Opinion: MAHA is rewriting the vocabulary of American mental health care
background ▾
- •MAHA is executing a strategic vocabulary shift ("treatment" → "wellness," "medication" → "dependency crisis") that rhetorically downgrades pharmacotherapy as a mental health pillar, reframing it as overmedicalization rather than evidence-based care
- •NIH grant terminations disproportionately hit NIMH in early 2025, and proposed OMB policy would subject post-peer-review study funding to political appointee veto, creating regulatory risk for psychiatric research
- •Watch for impact on psychiatric drug development pipelines, trial recruitment for psychotropic medications, and potential formulary/reimbursement pressure as payers and policymakers absorb MAHA messaging around deprescribing
Policy•KFF•Jul 16, 2026
KFF Tracker: U.S. Global Health Programs by Country and Region
background ▾
- •U.S. global health funding spans multiple therapeutic areas and 80+ countries, signaling continued government commitment to infectious disease and public health initiatives that may create downstream demand for vaccines and treatments
Policy•KFF•Jul 16, 2026
Why Do We Hear More About High Drug Prices Than About Hospital Prices?
background ▾
- •Hospitals account for 40% of national health spending growth (2022-2024) yet receive less policy scrutiny than drug prices
Market Access
Market Access•Fierce Biotech•Jul 16, 2026
Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market
background ▾
- •Lilly's $2.8B upfront acquisition signals major pharma's commitment to psychedelic-based psychiatry and direct challenge to J&J's Spravato dominance in TRD
- •BPL-003 shows operational advantages over Spravato—faster patient discharge and maintained efficacy through Day 57—that could streamline clinical workflows and improve patient experience
- •Success depends on phase 3 trial outcomes and DEA rescheduling of 5-MeO-DMT and DMT; regulatory pathway for psychedelics remains evolving and uncertain
Eli LillyAtaiBeckleyJohnson & JohnsonBPL-003VLS-01Spravato
→ Read original articleMarket Access•Fierce Biotech•Jul 17, 2026
Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal
background ▾
- •MTX652 is a phase 2-ready USP30 inhibitor for AKI that completed phase 1 with a mechanistic rationale focused on mitochondrial autophagy; Dimerix now owns the asset and has FDA approval to advance it in the U.S.
- •The deal structure is heavily backloaded ($175M of $287M in milestones tied to sales), reflecting Mission's urgent need for non-dilutive funding and Dimerix's strategic bet on a stalled but validated asset.
- •Watch for Dimerix's phase 2 initiation timeline and interim data readout; unclear whether DMX-652 will differentiate from other AKI approaches or achieve the development pace needed to justify the milestone structure.
DimerixMission TherapeuticsAmicus TherapeuticsMTX652DMX-652MTX325
→ Read original articleMarket Access•Fierce Biotech•Jul 16, 2026
Vogenx joins the IPO queue to fund phase 2-stage metabolic drug
background ▾
- •Mizagliflozin has completed phase 2 trials in post-bariatric hypoglycemia showing statistically significant reduction in glucose absorption and insulin secretion; phase 2b initiation expected in 2024
- •Lexicon's Inpefa (sotagliflozin), the first FDA-approved SGLT1/SGLT2 inhibitor, validates the modality for heart failure and metabolic indications, de-risking Vogenx's approach
- •Watch for IPO pricing and launch timing; phase 2b PBH trial initiation and gastroparesis phase 2 timeline (2027) will be key milestones for valuation and investor confidence
VogenxKissei PharmaceuticalLexicon PharmaceuticalsmizagliflozinInpefasotagliflozin
→ Read original articleMarket Access•Endpoints News•Jul 16, 2026
Mirador unveils part of pipeline with drug from Kira to rival Tavneos
background ▾
- •Mirador is emerging from stealth with a Tavneos competitor candidate, signaling intent to compete in the high-value complement inhibition market
- •The asset originated from Kira Biotech acquisition, indicating Mirador's strategy of in-licensing to build pipeline rather than internal R&D
Mirador TherapeuticsKira BiotechTavneos
→ Read original articleMarket Access•Endpoints News•Jul 16, 2026
What health system execs are talking about
background ▾
Clinical Trials
Clinical Trials•Fierce Biotech•Jul 17, 2026
GSK axes key cough drug candidate after phase 3 data end blockbuster hopes
background ▾
- •Camliprixant failed to demonstrate sustained efficacy in chronic cough despite initial promise—primary endpoint missed at Week 24 in Calm-2 trial and both high and low doses fell short on secondary endpoints
- •The termination eliminates a potential £2.5+ billion peak sales driver that GSK had counted on to bridge its ambitious £40 billion 2031 revenue target, with analyst forecasts already skeptical of achieving that goal
- •Watch for Phase 2b IBS data in March 2027 to determine whether camliprixant has clinical utility in a different indication; also monitor whether GSK identifies alternative chronic cough candidates or accelerates other pipeline assets to compensate for this loss
GSKBellus HealthMerck & Co.camliprixantgefapixant
→ Read original articleClinical Trials•Fierce Biotech•Jul 16, 2026
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
background ▾
- •Zasocitinib demonstrated substantially superior efficacy versus Otezla and placebo in high-impact treatment sites (scalp, palms/soles), with 75-77% clear/almost-clear scalp psoriasis outcomes versus 42-30% for Otezla and 7-13% for placebo
- •Once-daily dosing with rapid and durable response addresses key patient preferences, and the drug's 24-hour IL23 inhibition mechanism may offer competitive advantages over Sotyktu despite similar class
- •FDA submission expected within Takeda's current financial year; pivotal regulatory decision and market positioning relative to approved TYK2 inhibitors will be critical to validate $3-6 billion peak sales forecast
TakedaAmgenBristol Myers SquibbzasocitinibOtezlaSotyktu
→ Read original articleClinical Trials•Fierce Biotech•Jul 16, 2026
Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs
background ▾
- •Phase 1 trial of cord-derived MSC therapy in newborns with IVH and HIE showed 0% mortality, no serious adverse events, and no cerebral palsy in 9 dosed patients—exceptional early safety profile in a disease with 46% first-year mortality.
- •Axiom's "conditioning" approach (growing cells in disease-mimicking environment without genetic engineering) and intraventricular delivery bypass regulatory manufacturing and biodistribution hurdles that derailed competitors like Mesoblast's Ryoncil (two FDA rejections before 2024 approval).
- •Company plans phase 2b initiation and rapid expansion to adult ischemic stroke, potentially transforming a rare pediatric indication into a blockbuster-scale indication if efficacy translates.
Axiom BiosciencesMedinnoMesoblastWharton jelly MSC therapy (umbilical cord-derived mesenchymal stem cells)Ryoncil
→ Read original articleClinical Trials•Fierce Biotech•Jul 16, 2026
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
background ▾
- •Soficitinib achieved statistically significant F-VASI improvement (41.2% high dose, 38.8% low dose vs. 2.2% placebo) and will advance to phase 3, establishing InnoCare as a serious competitor in the vitiligo TYK2 inhibitor space
- •The vitiligo program is one of six ongoing mid-to-late-stage indications for InnoCare's TYK2 portfolio, including atopic dermatitis, CSU, psoriasis, and prurigo nodolaris, suggesting broad commercial potential if safety and efficacy hold
- •Watch for detailed Phase 3 vitiligo data, comparative efficacy/safety profiles versus Takeda and BMS candidates, and regulatory pathway decisions in key markets (particularly China and potential US/EU expansion)
InnoCare PharmaIncyteTakedasoficitinibICP-332ICP-488
→ Read original articleClinical Trials•STAT News•Jul 16, 2026
Predicting biotech clinical trials and a new Alzheimer’s drug controversy
background ▾
- •Kalshi prediction markets entering biotech sector introduces financial betting mechanisms for clinical trial outcomes and regulatory decisions, raising bioethical concerns about trial integrity and stakeholder conflicts of interest
- •Biogen's experimental tau-lowering Alzheimer's drug showed tau reduction and cognitive decline slowing in mid-stage trial, but mixed or ambiguous data sparked expert skepticism about clinical meaningfulness and regulatory path forward
- •Monitor Biogen's phase 3 trial progression and potential FDA guidance on tau biomarker-driven approvals; track regulatory response to prediction market expansion in biotech
KalshiBiogenBiogen tau-lowering drug (experimental, INN not specified)
→ Read original article